Seaport Therapeutics, Inc. (SPTX)
| Market Cap | 1.20B |
| Revenue (ttm) | n/a |
| Net Income | -134.69M |
| EPS | -8.50 |
| Shares Out | 53.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,193 |
| Open | 21.20 |
| Previous Close | 21.12 |
| Day's Range | 21.20 - 22.67 |
| 52-Week Range | 14.85 - 28.38 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.00 (+65.25%) |
| Est. Earnings | Nov 5, 2026 |
About SPTX
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SPTX stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 65.25% from the latest price.
News
Seaport Therapeutics Slides: Corporate presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Seaport Therapeutics Slides: Conference presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines...
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.
Seaport Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
The company presented its neuroscience-focused pipeline, highlighting the Glyph platform's ability to overcome oral bioavailability and liver toxicity issues. Lead programs GlyphAllo and GlyphAgo target depression and anxiety with promising clinical data and registration-enabling trials planned. The platform's versatility and AI-driven efficiencies position it for broader applications.
Seaport Therapeutics announces Phase 1 Trial of GlyphAllo met primary endpoint
Seaport Therapeutics (SPTX) announced positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo, a novel, Glyphed oral prodrug of allopregnanolone, in healthy volunteers. The tri...
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.
Seaport Therapeutics Slides: Corporate presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference.
Seaport Therapeutics initiated with a Buy at Jones
Jones analyst Justin Walsh initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $32 price target The clinical-stage biotechnology company is developing novel treatments for depressi...
Seaport Therapeutics reports Q2 EPS ($1.78), consensus (66c)
“The second quarter of 2026 was marked by two major milestones for Seaport – positive results from our Phase 1 proof-of-concept trial of GlyphAgo and the successful completion of our…
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
Seaport Therapeutics Earnings release: Q2 2026
Seaport Therapeutics released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Seaport Therapeutics Quarterly report: Q2 2026
Seaport Therapeutics has published its Q2 2026 quarterly earnings report on August 3, 2026.
Seaport Therapeutics Slides: Corporate presentation
Seaport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 31, 2026.
Seaport Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $50 price target Seaport is an emerging biopharmaceutical company focusing on develop...
Seaport Therapeutics participates in a conference call with JPMorgan
JPMorgan holds a conference call with management on July 14 at 3 pm. Webcast Link
Seaport Therapeutics initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of Seaport Therapeutics (SPTX) with a Peer Perform rating and no price target We the firm likes the company’s Glyph platform, it expects…
Seaport Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company presented its neuropsychiatry-focused pipeline, highlighting the Glyph platform's ability to improve oral bioavailability and safety of known drugs. Key milestones include phase II-B and driving study data for GlyphAllo in 2026–2027 and phase II studies for GlyphAgo in 2028, with funding secured into 2029.
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.
Seaport Therapeutics reports Q1 EPS ($10.34) vs. ($5.65) last year
“The first quarter of 2026 was filled with meaningful progress for Seaport, and we significantly advanced the clinical development of our lead GlyphAllo and GlyphAgo programs,” said Daphne Zohar, CEO.
Seaport Therapeutics sees cash runway into 2029
Cash, cash equivalents, and investments totaled $212.6 million as of March 31, 2026. Subsequent to March 31, 2026, Seaport completed its IPO, in which the Company raised gross proceeds of…
Seaport announces data from MAD part of Phase 1 trial of GlyphAgo
Seaport Therapeutics (SPTX) announced positive data from the multiple-ascending dose, MAD, portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo, a novel, Glyphed...
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers.